标题
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-05-07
DOI
10.3389/fphar.2021.692574
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
- (2020) Jinyun Dong et al. DRUG RESISTANCE UPDATES
- Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation
- (2020) Li Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
- (2020) Hao Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PROTACs: A novel strategy for cancer therapy
- (2020) Jing Liu et al. SEMINARS IN CANCER BIOLOGY
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
- (2020) Steven Kregel et al. NEOPLASIA
- First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
- (2020) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance
- (2020) Li Yuan et al. Molecular Cancer
- Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
- (2020) Si-Min Qi et al. Frontiers in Cell and Developmental Biology
- Aspeterreurone A, a Cytotoxic Dihydrobenzofuran–Phenyl Acrylate Hybrid from the Deep-Sea-Derived Fungus Aspergillus terreus CC-S06-18
- (2020) Weiyi Wang et al. JOURNAL OF NATURAL PRODUCTS
- Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
- (2020) De-Hua Yu et al. Frontiers in Oncology
- The E2 ubiquitin-conjugating enzyme UbcH5c: an emerging target in cancer and immune disorders
- (2020) Yuan Zhou et al. DRUG DISCOVERY TODAY
- The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?
- (2020) Jing-Li Xu et al. Frontiers in Cell and Developmental Biology
- The PROTAC technology in drug development
- (2019) Yutian Zou et al. CELL BIOCHEMISTRY AND FUNCTION
- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
- (2019) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Degrading proteins in animals: “PROTAC”tion goes in vivo
- (2019) Jianping Guo et al. CELL RESEARCH
- Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
- (2019) Miriam Girardini et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
- (2019) George M Burslem et al. CANCER RESEARCH
- The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
- (2019) Helei Hou et al. Cancer Cell International
- MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53
- (2019) Wei Wang et al. CANCER LETTERS
- Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
- (2019) Jay C. Groppe Expert Opinion on Drug Discovery
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
- (2019) Nobumichi Ohoka et al. ACS Chemical Biology
- Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells
- (2019) Xupeng Mu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
- (2019) Xiuyun Sun et al. BIOCHEMISTRY
- Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3
- (2019) Xuebao Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2019) Quanju Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-β signaling pathway
- (2019) Dai-Yu Sun et al. LIFE SCIENCES
- Targeting MDM2 for novel molecular therapy: Beyond oncology
- (2019) Wei Wang et al. MEDICINAL RESEARCH REVIEWS
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
- (2019) Chengcheng Shi et al. Cell Death & Disease
- A novel strategy to block mitotic progression for targeted therapy
- (2019) Junlong (Jack) Chi et al. EBioMedicine
- New Promise and Opportunities for Allosteric Kinase Inhibitors
- (2019) Xiaoyun Lu et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism
- (2019) Michael Winzker et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide
- (2019) Fangqing Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
- (2019) Saul Jaime-Figueroa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of selective mono or dual PROTAC degrader probe of CDK isoforms
- (2019) Fei Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α
- (2019) Yuxuan Dai et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Biological Evaluation of MEK PROTACs
- (2019) Stefan Vollmer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
- (2019) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
- (2019) Kidae Kim et al. Scientific Reports
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- Recent Advances in the Development of Indazole-based Anticancer Agents
- (2018) Jinyun Dong et al. ChemMedChem
- VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
- (2018) Jing Zhang et al. SCIENCE
- CrbnI391Vis sufficient to conferin vivosensitivity to thalidomide and its derivatives in mice
- (2018) Emma C. Fink et al. BLOOD
- Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer
- (2018) Taavi Neklesa et al. CANCER RESEARCH
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Role of HIF-1 in Cancer Progression: Novel Insights. A Review
- (2018) Aldo Pezzuto et al. CURRENT MOLECULAR MEDICINE
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-β/Smad signaling
- (2018) Guoliang Dai et al. PHYTOMEDICINE
- Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)
- (2018) Nobumichi Ohoka et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Targeted protein degradation by PROTACs
- (2017) Taavi K. Neklesa et al. PHARMACOLOGY & THERAPEUTICS
- Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199
- (2017) Kiran Naqvi et al. Expert Review of Hematology
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen
- (2017) Jiang-Jiang Qin et al. Frontiers in Pharmacology
- Strategies and Approaches of Targeting STAT3 for Cancer Treatment
- (2016) Steffanie L. Furtek et al. ACS Chemical Biology
- Small-Molecule PROTACS: New Approaches to Protein Degradation
- (2016) Momar Toure et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
- (2015) Dennis L. Buckley et al. ACS Chemical Biology
- Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling
- (2015) Natura Myeku et al. NATURE MEDICINE
- Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
- (2015) Jianhui Chang et al. NATURE MEDICINE
- Targeting Cdc20 as a novel cancer therapeutic strategy
- (2015) Lixia Wang et al. PHARMACOLOGY & THERAPEUTICS
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- FDA-approved small-molecule kinase inhibitors
- (2015) Peng Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
- (2013) Kadoaki Ohashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Polycomb-Dependent H3K27me1 and H3K27me2 Regulate Active Transcription and Enhancer Fidelity
- (2013) Karin J. Ferrari et al. MOLECULAR CELL
- Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
- (2012) Dennis L. Buckley et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
- (2012) Dennis L. Buckley et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins
- (2010) Yukihiro Itoh et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Impact of linker length on the activity of PROTACs
- (2010) Kedra Cyrus et al. Molecular BioSystems
- IAP-targeted therapies for cancer
- (2008) E C LaCasse et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started